DOCK8 and hyperinsulinemic hypoglycemia, familial, 4: Our findings encourage the pursuit of CRISPR/Cas-based gene editing approaches, which may constitute more precise, affordable, and low-risk definitive treatment options for DOCK8 deficiency.